Assembly Biosciences Net Income
| ASMB Stock | USD 25.71 0.71 2.69% |
As of the 30th of January, Assembly Biosciences shows the Standard Deviation of 3.66, risk adjusted performance of (0.02), and Mean Deviation of 2.71. Assembly Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Assembly Biosciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 5.5251 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -36.2 M | -38 M | |
| Net Loss | -36.2 M | -38 M | |
| Net Loss | -83.8 M | -88 M | |
| Net Loss | (6.02) | (6.32) | |
| Net Income Per E B T | 0.91 | 0.61 |
Assembly | Net Income | Build AI portfolio with Assembly Stock |
Analyzing Assembly Biosciences's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Assembly Biosciences's current valuation and future prospects.
Latest Assembly Biosciences' Net Income Growth Pattern
Below is the plot of the Net Income of Assembly Biosciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Assembly Biosciences financial statement analysis. It represents the amount of money remaining after all of Assembly Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Assembly Biosciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Assembly Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (40.18 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Assembly Net Income Regression Statistics
| Arithmetic Mean | (51,448,921) | |
| Coefficient Of Variation | (64.28) | |
| Mean Deviation | 26,470,173 | |
| Median | (40,177,000) | |
| Standard Deviation | 33,070,427 | |
| Sample Variance | 1093.7T | |
| Range | 121.1M | |
| R-Value | (0.45) | |
| Mean Square Error | 925.1T | |
| R-Squared | 0.21 | |
| Significance | 0.07 | |
| Slope | (2,979,225) | |
| Total Sum of Squares | 17498.4T |
Assembly Net Income History
Other Fundumenentals of Assembly Biosciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Assembly Biosciences Net Income component correlations
Assembly Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Assembly Biosciences is extremely important. It helps to project a fair market value of Assembly Stock properly, considering its historical fundamentals such as Net Income. Since Assembly Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Assembly Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Assembly Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Assembly Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.60) | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Assembly Biosciences's market price often diverges from its book value, the accounting figure shown on Assembly's balance sheet. Smart investors calculate Assembly Biosciences' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Assembly Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Assembly Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assembly Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Assembly Biosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Assembly Biosciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Assembly Biosciences.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Assembly Biosciences on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Assembly Biosciences or generate 0.0% return on investment in Assembly Biosciences over 90 days. Assembly Biosciences is related to or competes with Zura Bio, Foghorn Therapeutics, Immuneering Corp, Sagimet Biosciences, Enanta Pharmaceuticals, Aardvark Therapeutics, and Nautilus Biotechnology. Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for th... More
Assembly Biosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Assembly Biosciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Assembly Biosciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 18.53 | |||
| Value At Risk | (6.65) | |||
| Potential Upside | 5.85 |
Assembly Biosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Assembly Biosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Assembly Biosciences' standard deviation. In reality, there are many statistical measures that can use Assembly Biosciences historical prices to predict the future Assembly Biosciences' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.40) | |||
| Treynor Ratio | (0.12) |
Assembly Biosciences January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.11) | |||
| Mean Deviation | 2.71 | |||
| Coefficient Of Variation | (2,857) | |||
| Standard Deviation | 3.66 | |||
| Variance | 13.39 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.40) | |||
| Treynor Ratio | (0.12) | |||
| Maximum Drawdown | 18.53 | |||
| Value At Risk | (6.65) | |||
| Potential Upside | 5.85 | |||
| Skewness | (0.31) | |||
| Kurtosis | 1.08 |
Assembly Biosciences Backtested Returns
Assembly Biosciences secures Sharpe Ratio (or Efficiency) of -0.0666, which signifies that the company had a -0.0666 % return per unit of risk over the last 3 months. Assembly Biosciences exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Assembly Biosciences' Mean Deviation of 2.71, standard deviation of 3.66, and Risk Adjusted Performance of (0.02) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.13, which signifies a somewhat significant risk relative to the market. Assembly Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Assembly Biosciences is expected to follow. At this point, Assembly Biosciences has a negative expected return of -0.25%. Please make sure to confirm Assembly Biosciences' kurtosis, and the relationship between the value at risk and rate of daily change , to decide if Assembly Biosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.32 |
Poor reverse predictability
Assembly Biosciences has poor reverse predictability. Overlapping area represents the amount of predictability between Assembly Biosciences time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Assembly Biosciences price movement. The serial correlation of -0.32 indicates that nearly 32.0% of current Assembly Biosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.32 | |
| Spearman Rank Test | -0.41 | |
| Residual Average | 0.0 | |
| Price Variance | 8.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Assembly Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Assembly Biosciences reported net income of (40.18 Million). This is 111.77% lower than that of the Biotechnology sector and 157.36% lower than that of the Health Care industry. The net income for all United States stocks is 107.04% higher than that of the company.
Assembly Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Assembly Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Assembly Biosciences could also be used in its relative valuation, which is a method of valuing Assembly Biosciences by comparing valuation metrics of similar companies.Assembly Biosciences is currently under evaluation in net income category among its peers.
Assembly Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Assembly Biosciences from analyzing Assembly Biosciences' financial statements. These drivers represent accounts that assess Assembly Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Assembly Biosciences' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 288.1M | 100.8M | 45.0M | 94.8M | 85.3M | 168.1M | |
| Enterprise Value | 238.8M | 61.7M | 27.5M | 59.5M | 53.5M | 50.9M |
Assembly Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Assembly Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Assembly Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Assembly Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Assembly Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Assembly Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Assembly Biosciences' value.| Shares | Gsa Capital Partners Llp | 2025-06-30 | 14.8 K | State Street Corp | 2025-06-30 | 14 K | Man Group Plc | 2025-06-30 | 13.2 K | Ubs Group Ag | 2025-06-30 | 2.9 K | Barclays Plc | 2025-06-30 | 2.8 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.1 K | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 302 | Northwestern Mutual Wealth Management Co | 2025-06-30 | 260 | Tower Research Capital Llc | 2025-06-30 | 250 | Vanguard Group Inc | 2025-06-30 | 253.8 K | B Group, Inc | 2025-06-30 | 189.3 K |
Assembly Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (1.04) % | ||||
| Operating Margin | (1.01) % | ||||
| Current Valuation | 205.49 M | ||||
| Shares Outstanding | 15.82 M | ||||
| Shares Owned By Insiders | 32.29 % | ||||
| Shares Owned By Institutions | 56.20 % | ||||
| Number Of Shares Shorted | 1.57 M | ||||
| Price To Earning | (10.58) X | ||||
| Price To Book | 2.38 X | ||||
| Price To Sales | 11.24 X | ||||
| Revenue | 28.52 M | ||||
| Gross Profit | (24.65 M) | ||||
| EBITDA | (45.29 M) | ||||
| Net Income | (40.18 M) | ||||
| Cash And Equivalents | 116.69 M | ||||
| Cash Per Share | 2.41 X | ||||
| Total Debt | 3.09 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 8.31 X | ||||
| Book Value Per Share | 11.55 X | ||||
| Cash Flow From Operations | (51.12 M) | ||||
| Short Ratio | 11.10 X | ||||
| Earnings Per Share | (4.60) X | ||||
| Target Price | 47.75 | ||||
| Number Of Employees | 73 | ||||
| Beta | 1.15 | ||||
| Market Capitalization | 417.89 M | ||||
| Total Asset | 119.17 M | ||||
| Retained Earnings | (825.92 M) | ||||
| Working Capital | 67.7 M | ||||
| Current Asset | 68.37 M | ||||
| Current Liabilities | 3.4 M | ||||
| Net Asset | 119.17 M |
About Assembly Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Assembly Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Assembly Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Assembly Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Assembly Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.60) | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Assembly Biosciences's market price often diverges from its book value, the accounting figure shown on Assembly's balance sheet. Smart investors calculate Assembly Biosciences' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Assembly Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Assembly Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assembly Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.